Miltefos 50 Capsule

Visceral leishmaniasis, Mycosis fungoides, Skin metastases of breast cancer

Adult : PO Visceral Leishmaniasis 100-150 mg/day for 28 days.

Child: PO 2.5 mg/kg/day bid >12 y: 30–44 kg: 100 mg/day bid >45 kg: 150 mg/day tid

Pregnancy, lactation, concurrent radiation therapy.

Metastases grown over breast implants. Increased serum creatinine, ALT, AST, bilirubin reported; monitor. Thrombocytopenia reported; monitor platelets Stevens-Johnson syndrome reported; discontinue if an exfoliative or bullous rash occurs Lactation: Unknown if distributed in human breast milk; avoid breastfeeding during therapy and for 5 months following therapy

D Pregnancy Category: D (see Black Box Warnings); Human pregnancy data are not available; however, embryofetal toxicity, including death and teratogenicity, was observed in embryo-fetal studies in rats and rabbits Clinical considerations: During pregnancy, visceral leishmaniasis may be life-threatening for the mother and may result in adverse fetal outcomes, including spontaneous abortion, congenital disease due to vertical transmission, small for gestational age newborn, and severe anemia Lactation: Unknown if distributed in human breast milk; avoid breastfeeding during therapy and for 5 months following therapy

>10% Visceral leishmaniasis Increased transaminases, <3 x ULN (94%),Decreased platelets <150,000 (62%),Vomiting (37.8%),Decreased appetite (23.1%),Diarrhea (20.4%) 1-10% Visceral leishmaniasis Increased serum creatinine, >1.5 x baseline (10%),Asthenia (6.3%),Increased transaminases, 3-5 x ULN (6%),Decreased platelets <50,000 (2.4%)

Miltefosine is a phospholipid derivative thought to work by disrupting cell-membrane function.

Miltefos 50 50mg Capsule manufactured by Popular Pharmaceuticals Ltd.. Its generic name is Miltefosine.